$1.76M Grant to Support Trial of Jotrol, Form of Resveratrol, in Early Alzheimer’s

$1.76M Grant to Support Trial of Jotrol, Form of Resveratrol, in Early Alzheimer’s
The National Institute on Aging, a division of the National Institutes of Health, is awarding a $1.76 million, one-year grant to support a Phase 1 clinical trial investigating oral Jotrol as a potential treatment of early stage Alzheimer's disease. The study is to be called "Safety and Pharmacokinetics of JOTROL for Alzheimer's Disease." Further information, including an anticipated launch date, was not available in a press release. Jotrol, made by Jupiter Orphan Therapeutics, is a more biologically active formulation of resveratrol, a naturally occurring anti-inflammatory and antioxidant molecule found in certain foods, including red wine, red grapes, some berries, and peanuts. A 1997 discovery linked resveratrol, consumed in red wine in that case, to a lower dementia risk. Subsequent studies have identified other potentially neuroprotective effects. These include reducing markers of brain inflammation and oxidative stress, and preserving the function of mitochondria — the organell
Subscribe or to access all post and page content.